El dasatinib parece asociarse con una adecuada respuesta hematológica en quienes coexiste una mastocitosis sistémica y una neoplasia hematológica. Los nuevos inhibidores de la tirosina quinasa representan una alternativa para optimizar el pronóstico de estos enfermos.

---

Bibliografía del caso clínico


1. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (Mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, IARC Press: Lyon, France. vol 2. pp. 54-63, 2008.
2. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113:5727-36, 2009.
3. Sperr WR, Horny H-P, Lechner K, et al. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 37:473-86, 2000.
4. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic nonmast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 127:140-2, 2002.
5. Pullarkat ST, Sedarat F, Paquette R, et al. Systemic mastocytosis with plasma cell dyscrasia: report of a case. Leuk Res 32:1160-3, 2008.
6. Horny H-P, Sotlar K, Stellmacher F, et al. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 59:264-8, 2006.
7. Tzankov A, Sotlar K, Muhlematter D, et al. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol 61:958-61, 2008.
8. Pullarkat VA, Bueso-Ramos C, Lai R, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 73:12-7, 2003.
9. Du S, Rashidi HH, Le DT, Kipps TJ, et al. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol 3:448-57, 2010.
10. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:10560-4, 1995.
11. Hungness SI, Akin C. Mastocytosis: advances in diagnosis and treatment. Curr Allergy Asthma Rep 7:248-54, 2007.
12. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115-24, 2002.
13. Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 23:139-52, 2004.
14. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906-15, 2008.
15. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33:735-41, 2009.
16. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84:790-4, 2009.
17. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31:686-92, 2003.
18. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115-24, 2002.
19. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-4, 2002.
20. Zermati Y, De Sepulveda P, Féger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22:660-4, 2003.
21. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-32, 2000.
22. Yamada Y, Cancelas JA. FIP1L1/PDGFR alpha-associated systemic mastocytosis. Int Arch Allergy Immunol 152(Suppl.1):101-5, 2010.
23. Lahortiga I, Akin C, Cools J, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93:49-56, 2008.
24. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481-4, 2009.
25. Pagano L, Valentini CG, Caira M, et al Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 88:483-8, 2008.
26. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 362:535-6, 2003.
27. Droogendijk HJ, Kluin-Nelemans HJ, et al.Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107:345-51, 2006.
28. Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 30:1201-5, 2006.
29. Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112:1655-7, 2008.
30. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-5, 2004.
31. Pardanani A, Verstovsek S. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease. Cancer J 13:384-91, 2007.
32. Zhang LY, Smith ML, Schultheis B, et al.A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 30:373-8, 2006.
33. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to Imatinib therapy. Blood 2003.
34. Heinrich MC, Joensuu H, Demetri GD, et al. Imatinib Target Exploration Consortium Study B2225. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14:2717-25, 2008.
35. Purtill D, Sinniah R, Cooney J, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haem 80:456-8, 2008.
36. Benz R, Boesiger J, Fehr J. Systemic mastocytosis with c-KITD816V mutation treated with dasatinib. Blood 110:258b, 2007.
37. Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 38:869-73, 2008.
38. Gotlib J, George TI, Corless C, et al. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase ii trial. Blood 110:3536, 2007.
39. Verstovsek S, Akin C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30:1365-70, 2006.
40. Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP, Gratwohl A, Rafferty T, Resta D, Gattermann N.A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Blood 108:2703, 2006.
41. Yavuz A, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100:661-665, 2002
42. Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 28:140-147, 2000.
43. Nagai S, Ichikawa M, Takahashi T, et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia Exp Hematol 35:1747-52, 2007.
44. Pullarkat V, Bedell V, Kim Y, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31:261-5, 2007.
45. McClintock-Treep SA, Horny HP, Sotlar K, Foucar MK, Reichard KK. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation. J Clin Pathol 62:1147-9, 2009. Artículos publicados por el autor (selección)
Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Koul S, Chen J, Savoie A, Ustun C, Jillella A, Levine RL, Bhalla K. Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2-V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells Blood 114(114):33-33, 2009

Tanna Saloni, Ustun C. Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia; harm or benefit? International Journal of Hematology 90:597-600, 2009

Ustun C, Deremer D, Jillella A, Bhalla K. Investigational drugs targeting flt3 for leukemia Expert Opinion on Investigational Drugs 18:1445-1456, 2009

Fiskus W, Wang Y, Sreekumar A, Buckley K, Shi H, Jillella A, Ustun C, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells Blood 114:2733-2743, 2009

Subbannan K, Ustun C, Natarajan K, et al. Spleen related complications and implications of splenectomy in patients with hemoglobin SC disease International Journal of Hematology 83:258-260, 2009

Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT(D816V) Leukemia Research 33:735-741, 2009

Reid-Nicholson M, Nayak A, McDonald K, Crawford J, Jillella A, Ramalingham P. Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome Annals of Hematology 88:351-358, 2009

Ustun C, Jillella AP, Salama ME. Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient American Journal of Hematology 84:386-387, 2009

Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.